S
Suzhou Yihe Pharmaceutical
Inhalation formulation solutions providing targeted drug delivery systems
About Suzhou Yihe Pharmaceutical
Suzhou Yihe Pharmaceutical, also known as Inhal Pharma, is a company specializing in the research and development of inhalation formulations, devices, and filling equipment. The company was co-founded in 2020 by Professor Jingxu Zhu, a Fellow of the Royal Society of Canada and the Canadian Academy of Engineering, and Dr. Kaiqi Shi. Professor Zhu's team has been engaged in inhalation drug delivery research since 1994. The company's headquarters, Ningbo Inhal Pharma Co., Ltd., is located in Ningbo and focuses on the development and production of inhalation devices and filling equipment. In 2021, the company established its Suzhou R&D Center, which concentrates on the development of inhalation formulations.
Inhal Pharma aims to provide turnkey solutions in the inhalation drug delivery sector for global pharmaceutical companies. The firm's core technologies include ultrafine powder preparation, precise quantitative repackaging of ultrafine dry powder drugs, and the design and development of low-resistance inhalation flow channels. They develop both carrier-free and carrier-based formulations. The company's product and service offerings cover the design and development of various dry powder inhalers, such as capsule-based, disc-based, blister-based, and reservoir-based types, alongside services like 3D printing and numerical simulation. In October 2023, the company announced the completion of a Series A financing round, raising over 50 million Yuan RMB.
Source: Dealroom company dataNews
Open roles
Suzhou Yihe Pharmaceutical in its local ecosystem
The Suzhou Yihe Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Saiying Capital- YHYishang Huicheng
- SFShaanxi Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Yihe Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Yihe Pharmaceutical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

